288 related articles for article (PubMed ID: 29936243)
1. Behavioral and cellular dopamine D
Lanza K; Meadows SM; Chambers NE; Nuss E; Deak MM; Ferré S; Bishop C
Neuropharmacology; 2018 Aug; 138():304-314. PubMed ID: 29936243
[TBL] [Abstract][Full Text] [Related]
2. Reciprocal cross-sensitization of D1 and D3 receptors following pharmacological stimulation in the hemiparkinsonian rat.
Lanza K; Chemakin K; Lefkowitz S; Saito C; Chambers N; Bishop C
Psychopharmacology (Berl); 2020 Jan; 237(1):155-165. PubMed ID: 31435690
[TBL] [Abstract][Full Text] [Related]
3. Dopamine receptor cooperativity synergistically drives dyskinesia, motor behavior, and striatal GABA neurotransmission in hemiparkinsonian rats.
Kiessling CY; Lanza K; Feinberg E; Bishop C
Neuropharmacology; 2020 Sep; 174():108138. PubMed ID: 32492451
[TBL] [Abstract][Full Text] [Related]
4. Dopamine D3 Receptor Modulates l-DOPA-Induced Dyskinesia by Targeting D1 Receptor-Mediated Striatal Signaling.
Solís O; Garcia-Montes JR; González-Granillo A; Xu M; Moratalla R
Cereb Cortex; 2017 Jan; 27(1):435-446. PubMed ID: 26483399
[TBL] [Abstract][Full Text] [Related]
5. L-DOPA treatment selectively restores spine density in dopamine receptor D2-expressing projection neurons in dyskinetic mice.
Suárez LM; Solís O; Caramés JM; Taravini IR; Solís JM; Murer MG; Moratalla R
Biol Psychiatry; 2014 May; 75(9):711-22. PubMed ID: 23769604
[TBL] [Abstract][Full Text] [Related]
6. 5alpha-reductase inhibitors dampen L-DOPA-induced dyskinesia via normalization of dopamine D1-receptor signaling pathway and D1-D3 receptor interaction.
Fanni S; Scheggi S; Rossi F; Tronci E; Traccis F; Stancampiano R; De Montis MG; Devoto P; Gambarana C; Bortolato M; Frau R; Carta M
Neurobiol Dis; 2019 Jan; 121():120-130. PubMed ID: 30261284
[TBL] [Abstract][Full Text] [Related]
7. Dopamine D3 receptor stimulation underlies the development of L-DOPA-induced dyskinesia in animal models of Parkinson's disease.
Visanji NP; Fox SH; Johnston T; Reyes G; Millan MJ; Brotchie JM
Neurobiol Dis; 2009 Aug; 35(2):184-92. PubMed ID: 19118628
[TBL] [Abstract][Full Text] [Related]
8. Genetic suppression of the dopamine D3 receptor in striatal D1 cells reduces the development of L-DOPA-induced dyskinesia.
Lanza K; Centner A; Coyle M; Del Priore I; Manfredsson FP; Bishop C
Exp Neurol; 2021 Feb; 336():113534. PubMed ID: 33249031
[TBL] [Abstract][Full Text] [Related]
9. Overexpression of the dopamine D3 receptor in the rat dorsal striatum induces dyskinetic behaviors.
Cote SR; Chitravanshi VC; Bleickardt C; Sapru HN; Kuzhikandathil EV
Behav Brain Res; 2014 Apr; 263():46-50. PubMed ID: 24462727
[TBL] [Abstract][Full Text] [Related]
10. Behavioral and biochemical correlates of the dyskinetic potential of dopaminergic agonists in the 6-OHDA lesioned rat.
Carta AR; Frau L; Pinna A; Pontis S; Simola N; Schintu N; Morelli M
Synapse; 2008 Jul; 62(7):524-33. PubMed ID: 18435422
[TBL] [Abstract][Full Text] [Related]
11. Persistent activation of the D1R/Shp-2/Erk1/2 pathway in l-DOPA-induced dyskinesia in the 6-hydroxy-dopamine rat model of Parkinson's disease.
Fiorentini C; Savoia P; Savoldi D; Barbon A; Missale C
Neurobiol Dis; 2013 Jun; 54():339-48. PubMed ID: 23328768
[TBL] [Abstract][Full Text] [Related]
12. Buspirone anti-dyskinetic effect is correlated with temporal normalization of dysregulated striatal DRD1 signalling in L-DOPA-treated rats.
Azkona G; Sagarduy A; Aristieta A; Vazquez N; Zubillaga V; Ruíz-Ortega JA; Pérez-Navarro E; Ugedo L; Sánchez-Pernaute R
Neuropharmacology; 2014 Apr; 79():726-37. PubMed ID: 24333147
[TBL] [Abstract][Full Text] [Related]
13. Modulating mGluR5 and 5-HT1A/1B receptors to treat l-DOPA-induced dyskinesia: effects of combined treatment and possible mechanisms of action.
Iderberg H; Rylander D; Bimpisidis Z; Cenci MA
Exp Neurol; 2013 Dec; 250():116-24. PubMed ID: 24029003
[TBL] [Abstract][Full Text] [Related]
14. Identification of metabolite biomarkers for L-DOPA-induced dyskinesia in a rat model of Parkinson's disease by metabolomic technology.
Wang Y; Zhang GJ; Sun YN; Yao L; Wang HS; Du CX; Zhang L; Liu J
Behav Brain Res; 2018 Jul; 347():175-183. PubMed ID: 29551735
[TBL] [Abstract][Full Text] [Related]
15. Distinct patterns of dyskinetic and dystonic features following D1 or D2 receptor stimulation in a mouse model of parkinsonism.
Andreoli L; Abbaszadeh M; Cao X; Cenci MA
Neurobiol Dis; 2021 Sep; 157():105429. PubMed ID: 34153463
[TBL] [Abstract][Full Text] [Related]
16. Stronger Dopamine D1 Receptor-Mediated Neurotransmission in Dyskinesia.
Farré D; Muñoz A; Moreno E; Reyes-Resina I; Canet-Pons J; Dopeso-Reyes IG; Rico AJ; Lluís C; Mallol J; Navarro G; Canela EI; Cortés A; Labandeira-García JL; Casadó V; Lanciego JL; Franco R
Mol Neurobiol; 2015 Dec; 52(3):1408-1420. PubMed ID: 25344317
[TBL] [Abstract][Full Text] [Related]
17. Differential involvement of D1 and D2 dopamine receptors in L-DOPA-induced angiogenic activity in a rat model of Parkinson's disease.
Lindgren HS; Ohlin KE; Cenci MA
Neuropsychopharmacology; 2009 Nov; 34(12):2477-88. PubMed ID: 19606087
[TBL] [Abstract][Full Text] [Related]
18. Increased D1 dopamine receptor signaling in levodopa-induced dyskinesia.
Aubert I; Guigoni C; Håkansson K; Li Q; Dovero S; Barthe N; Bioulac BH; Gross CE; Fisone G; Bloch B; Bezard E
Ann Neurol; 2005 Jan; 57(1):17-26. PubMed ID: 15514976
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of D2 and D3 dopamine receptor selective compounds on L-dopa-dependent abnormal involuntary movements in rats.
Kumar R; Riddle LR; Griffin SA; Chu W; Vangveravong S; Neisewander J; Mach RH; Luedtke RR
Neuropharmacology; 2009; 56(6-7):956-69. PubMed ID: 19371586
[TBL] [Abstract][Full Text] [Related]
20. C57BL/6J mice exhibit reduced dopamine D3 receptor-mediated locomotor-inhibitory function relative to DBA/2J mice.
McNamara RK; Levant B; Taylor B; Ahlbrand R; Liu Y; Sullivan JR; Stanford K; Richtand NM
Neuroscience; 2006 Nov; 143(1):141-53. PubMed ID: 16938406
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
